This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Watson, Amneal fail to get order denying dismissal of Colcrys US antitrust case reconsidered

( April 25, 2022, 15:35 GMT | Official Statement) -- MLex Summary: Watson Laboratories and Amneal Pharmaceuticals have failed to convince a US judge to reconsider dismissing claims that they illegally conspired to delay market entry for a generic version of the anti-inflammatory drug Colcrys. US District Judge Mark A. Kearney said that Value Drug adequately pled a plausible motive belying Watson and Amneal’s argument about economic implausibility. “Our previous holding need not be reconsidered because the fact issues raised by Watson and Amneal’ argument formed the basis of our previous opinion although we did not spell them out.” Additionally, Kearney denied the company’s request for an interlocutory appeal.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections